Duphaston 60 tablets
An analogue of natural progesterone. Dydrogesterone in its molecular structure, chemical and pharmacological properties is very close to natural progesterone.
Compound: Each tablet contains:
Dydrogesterone 10 mg
Auxiliary components: lactose monohydrate , hypromellose , corn starch , colloidal silicon dioxide , magnesium stearate .
Properties: An analogue of natural progesterone. Dydrogesterone in its molecular structure, chemical and pharmacological properties is very close to natural progesterone. Due to the fact that dydrogesterone is not a testosterone derivative, it does not have the side effects of most synthetic progestogens, the so-called “androgenic” progestogens. Dydrogesterone does not have estrogenic, androgenic, anabolic, glucocorticoid and thermogenic activity. Being a progestogenic component of HRT in menopause, dydrogesterone helps to maintain the beneficial effect of estrogens on the blood lipid profile. However, unlike estrogens, which usually negatively affect the blood coagulation system, dydrogesterone does not affect coagulation parameters. Does not adversely affect carbohydrate metabolism and liver function. Dydrogesterone, when administered orally, selectively acts on the endometrium, thereby preventing an increased risk of endometrial hyperplasia and / or carcinogenesis in conditions of excess estrogens. It is indicated in all cases of endogenous progesterone deficiency. Dydrogesterone has no contraceptive action. In the treatment of dydrogesterone, the therapeutic effect is achieved without the suppression of ovulation or menstrual dysfunction. Dydrogesterone makes it possible to conceive and maintain pregnancy during treatment. Indications: Progesterone deficiency: endometriosis; infertility due to luteal insufficiency; threatening or habitual miscarriage (with progesterone deficiency); premenstrual tension syndrome; dysmenorrhea, irregular menstrual cycle; secondary amenorrhea (in complex therapy with estrogens); dysfunctional uterine bleeding. HRT: to neutralize the proliferative effect of estrogens on the endometrium in women with disorders caused by natural or surgical menopause with an intact uterus.
Dosage and administration: inside. The dose and treatment regimen is set individually, depending on the indications. The duration of therapy and doses may be adjusted according to the individual clinical response of the patient and the severity of the pathology.
Contraindications: Hypersensitivity to dydrogesterone; diagnosed or suspected progestogen-dependent neoplasms (eg, meningioma); bleeding from the vagina of unknown etiology; Liver dysfunction due to acute or chronic liver disease at present or in history (before normalization of liver function tests); malignant tumors of the liver at present or in history; breastfeeding period; porphyria at present or in history; age up to 18 years. When combined with estrogens (HRT): untreated endometrial hyperplasia; arterial and venous thrombosis, thromboembolism at present or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction, thrombophlebitis, cerebrovascular disorders of hemorrhagic and ischemic type); identified predisposition to venous or arterial thrombosis (resistance to activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (cardiolipin antibodies, lupus anticoagulant). With caution: depression, currently or in history; conditions that previously appeared or worsened during a previous pregnancy or previous use of sex hormones, such as cholestatic jaundice, herpes during pregnancy, severe pruritus, otosclerosis.
Precautionary measures: Before starting treatment with dihydrosterone for abnormal uterine bleeding, it is necessary to find out the cause of the bleeding. With prolonged use of dihydrosterone, periodic examinations by a gynecologist are recommended, the frequency of which is determined individually, but at least once every 6 months. Breakthrough bleeding or spotting may occur during the first months of treatment for abnormal uterine bleeding. If “breakthrough” bleeding or spotting occurs after a certain period of taking dihydrosterone or continues after a course of treatment, you should contact your doctor and conduct an appropriate additional examination, if necessary, do an endometrial biopsy to exclude neoplasms in the endometrium.
Side effects: From the hemopoietic system: rarely – hemolytic anemia. From the nervous system: often – migraine / headache